Effect of Danhong Injection in Relieving Blood Stasis of 65 Cases with Chronic Renal Failure Maintenance Hemodialysis

ZHOU Cheng; WANG Jian-gang; LI Zhen; YIN Jin-lei

doi:10.13422/j.cnki.syfjx.2015160167

您当前的位置：

首页 >

文章列表页 >

Effect of Danhong Injection in Relieving Blood Stasis of 65 Cases with Chronic Renal Failure Maintenance Hemodialysis

更新时间：2024-01-04

- Effect of Danhong Injection in Relieving Blood Stasis of 65 Cases with Chronic Renal Failure Maintenance Hemodialysis
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 21, Issue 16, Pages: 167-170(2015)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.2015160167
  CLC： R277.5
- Published：2015
- 稿件说明：
移动端阅览
ZHOU Cheng, WANG Jian-gang, LI Zhen, et al. Effect of Danhong Injection in Relieving Blood Stasis of 65 Cases with Chronic Renal Failure Maintenance Hemodialysis[J]. Chinese journal of experimental traditional medical formulae, 2015, 21(16): 167-170.
DOI：

ZHOU Cheng, WANG Jian-gang, LI Zhen, et al. Effect of Danhong Injection in Relieving Blood Stasis of 65 Cases with Chronic Renal Failure Maintenance Hemodialysis[J]. Chinese journal of experimental traditional medical formulae, 2015, 21(16): 167-170. DOI： 10.13422/j.cnki.syfjx.2015160167.

摘要

目的: 观察丹红注射液对慢性肾衰竭(CRF)维持性血液透析患者血瘀证的改善作用及对血栓形成的影响。方法: 将130例CRF维持性血液透析患者采用随机按数字表法分为对照组和观察组各65例。对照组服用双嘧达莫片

50 mg/次

3次/d

连续服用。观察组在对照组治疗的基础上给予丹红注射液30 mL注入0.9% 生理盐水100 mL

缓慢静脉滴注

1次/d。连续使用10 d为1个疗程

每月治疗1个疗程

两组均治疗3个疗程。于治疗前及治疗后1

3个月进行血瘀证评分;检测治疗前后血液流变学指标

纤维蛋白原(FIB)水平

D-二聚体(D-D)

血小板颗粒膜蛋白(CD62 P)

血小板溶酶体颗粒膜蛋白(CD63)

凝血酶敏感蛋白(TSP)

血栓素(TXB2)

6-酮-前列腺素F1α(6-Keto-PGF1α)变化情况。结果: 治疗后第2

3个月观察组血瘀证评分低于对照组(P <0.01);治疗后观察组血瘀证评分下降幅度多于对照组(P <0.01);治疗后观察组全血黏度(高切、低切)、血浆黏度和血小板聚集率等指标低于对照组(P <0.01);治疗后观察组TXB2

FIB和D-D水平均低于对照组(P <0.01)

6-Keto-PGF1α水平高于对照组(P <0.01);治疗后观察组CD62 P和TSP水平均低于对照组(P <0.05)

两组间CD63水平比较差异无统计学意义。结论: 丹红注射液能改善慢性肾衰竭维持性血液透析患者血瘀证积分

抑制了血小板的活化

改善了微循环

减轻了血液高凝状态

防止了血栓的形成。

Abstract

Objective: To observe the effect of Danhong injection in relieving blood stasis and thrombosis of patients with chronic renal failure (CRF) maintenance hemodialysis. Method: Totally 130 patients with CRF maintenance hemodialysis were divided into the observation group (65 cases) and the control group (65 cases) by the random numbers table method. Patients in the control group took Dipyridamole tablets

50 mg/time

3 times/day for continuing administration. In addition to the therapy of the control group

patients in the observation group was given 30 mL Danhong injection and 100 mL 0.9% saline solution for slow intravenous dripping

1 times/day. One treatment course was ten days

once a month. The total course lasted for 3 months. The blood stasis syndrome was scored at the first

second and third months before and after the treatment. The changes in blood rheology indexes

fibrinogen (FIB) level

D-dimmer (D-D)

platelet granule membrane protein (CD62 P)

lysosomes platelet granule membrane protein (CD63)

thrombin sensitive protein (TSP)

thromboxane (TXB2)

6-Ketone-prostaglandin F1α(6-Keto-PGF1α) were detected before and after the treatment. Result: The blood stasis syndrome scores in the observation group were lower than that in the control group at the second and third months after the treatment (P <0.01). The blood stasis syndrome score in the observation group declined faster than that in the control group at the second and third months after the treatment (P <0.01). After the treatment

the whole blood viscosity (high

low)

plasma viscosity and platelet aggregation rate in the observation group were higher than that in the control group (P <0.01). The levels of TXB2

FIB and D-D in the observation group were lower than that in the control group (P <0.01)

but with higher 6-Keto-PGF1α than that in the control group (P <0.01). The CD62 P and TSP in the observation group were less than that in the control group (P <0.05)

with no statistical significance in differences in CD63 between both groups. Conclusion: Danhong injection can relieve blood stasis among patients with chronic renal failure maintenance hemodialysis

inhibit platelet activation

enhance microcirculation

reduce high blood coagulation state

and prevent the thrombosis.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Danhong Injection to Curative Effect and Treating Different Types of Stable Angina of Blood Stasis Evaluation and Safety

Efficacy-driving Mechanism of Danhong Injection for Stable Angina Pectoris Based on Composition-activity Relationship of Target Modules

Exploring Modern Mechanism of Treating Diabetic Retinopathy and Coronary Heart Disease from Perspective of Blood Stasis Under Viewpoint of Treating Different Diseases with the Same Method

Comparison of Effect of Hirudo， Notoginseng Radix et Rhizoma， and Their Combinations on Renal Fibrosis in Rats with Chronic Renal Failure

Effect of Modified Zhenwutang on Interstitial Fibrosis in Rats with Chronic Renal Failure Based on IL-6/MMP-9/COL-Ⅳ Signaling Pathway

Related Author

ZHU Qin-ying

HUANG Xue-lian

TANG Ling

ZONG Wenjing

LIU Jun

YANG Wei

NIU Qikai

ZHANG Siqi

Related Institution

Institute of Basic Theory for Chinese Medicine，China Academy of Chinese Medical Sciences

Institute of Basic Research in Clinical Medicine，China Academy of Chinese Medical Sciences

Institute of Chinese Materia Medica， China Academy of Chinese Medical Sciences， State Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs， Institute of Chinese Materia Medica， China Academy of Chinese Medical Sciences

National Clincial Research Center for Cardiovascular Diseases of Traditional Chinese Medicine， Xiyuan Hospital，China Academy of Chinese Medical Sciences

College of Traditional Chinese Medicine， Chongqing Medical University

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰